Skip to main content

Table 7 TEAEs by sex in the crossover phase while receiving LDX with an incidence of ≥10% in the dose-optimization and/or crossover phase

From: Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day

AE-Preferred Term

Crossover Phase

 

Males

Females

 

(n = 87)

(n = 28)

 

n (%)

n (%)

Any AE

30 (34.5)

8 (28.6)

Abdominal pain upper

2 (2.3)

0 (0.0)

Affect lability

0 (0.0)

0 (0.0)

Decreased appetite

5 (5.7)

2 (7.1)

Headache

4 (4.6)

2 (7.1)

Insomnia

5 (5.7)

0 (0.0)

Irritability

1 (1.1)

0 (0.0)

Nausea

1 (1.1)

1 (3.6)

Back to article page

Child and Adolescent Psychiatry and Mental Health

ISSN: 1753-2000